Vicore launches COMPANION, a clinical study investigating the benefit of digital therapy on anxiety in patients with idiopathic pulmonary fibrosis (IPF)
· First clinical study with a digital therapy (DTx) in patients with IPF to address the psychological symptom burden in this disease · First patient enrolled in US pilot phase leading up to the US pivotal phase of the study with expected start in H2 2022 · DTx aims to form a part of a differentiated offering in rare lung disease Gothenburg, April 21, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company, today announces the first patient enrolled in the pilot phase of COMPANION[1], a clinical study of a digital cognitive behavioral therapy for